Results 241 to 250 of about 759,957 (341)

Reprogramming the Tumor Immune Microenvironment with ICAM‐1‐Targeted Antibody‒Drug Conjugates and B7‐H3‐CD3 Bispecific Antibodies

open access: yesAdvanced Science, EarlyView.
Reprogramming the tumor immune microenvironment is crucial for transforming immune “cold” tumors into “hot” inflammatory tumors. The investigation reveals that the combination of ICAM‐1‐Dxd with B7‐H3‐CD3 bispecific antibodies not only demonstrates significant inhibitory effects on tumor growth and metastasis but also plays a vital role in ...
Shoubing Zhou   +9 more
wiley   +1 more source

Novel broadly reactive monoclonal antibody protects against Pseudomonas aeruginosa infection. [PDF]

open access: yesInfect Immun
Mateu-Borrás M   +21 more
europepmc   +1 more source

IR783‐Stabilized Nanodrugs Enhance Anticancer Immune Response by Synergizing Oxidation Therapy and Epigenetic Modulation

open access: yesAdvanced Science, EarlyView.
IR783‐stabilized nanodrugs composed of NIR dye IR783, ROS inducer β‐lapachone, and epigenetic modulator CUDC101 are designed for breast cancer immunotherapy. The nanodrugs can not only promote cancer cell apoptosis through HDAC inhibition‐enhanced oxidation therapy but also reshape the immunosuppressive microenvironment, which provides a novel strategy
Jinzhao Liu   +6 more
wiley   +1 more source

A Novel Theranostic Strategy for Malignant Pulmonary Nodules by Targeted CECAM6 with 89Zr/131I‐Labeled Tinurilimab

open access: yesAdvanced Science, EarlyView.
This study investigates the integrated diagnostic and therapeutic strategy utilizing 89Zr/131I‐labeled tinurilimab for the management of malignant lung nodules, with a particular focus on lung adenocarcinoma (LUAD). CEACAM6, which is highly expressed in most LUAD patients, activates the Src/FAK signaling pathway, thereby promoting cell proliferation ...
Chongyang Chen   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy